Opaleye Management sells 28315 Eton Pharmaceuticals (ETON) shares on July 14
Rhea-AI Filing Summary
Eton Pharmaceuticals, Inc. ten percent owner Opaleye Management Inc., through a separately managed account and Opaleye, L.P., reported selling a total of 28,315 common shares on July 14, 2026 at a weighted average price of $37.5431 per share. After these indirect sales, the accounts held 40,000 and 2,665,000 shares, respectively, with Opaleye Management disclaiming beneficial ownership except for its pecuniary interest. The amendment states Opaleye Management is no longer subject to Section 16 reporting.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 28,315 shares
Net Sell
2 txns
Insider
Opaleye Management Inc.
Role
10% Owner
Sold
28,315 shs ($1.06M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.001 per share F3, F1, F4 | 15,000 | $37.5431 | $563K |
| Sale | Common Stock, par value $0.001 per share F3, F2, F4 | 13,315 | $37.5431 | $500K |
Holdings After Transaction:
Common Stock, par value $0.001 per share — 2,665,000 shares (Indirect, By Opaleye, L.P.);
Common Stock, par value $0.001 per share — 40,000 shares (Indirect, By Managed Account)
Footnotes (4)
- F1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
- F2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account.
- F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.0152 to $37.9148 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
- F4. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Key Figures
Total shares sold: 28315 shares
Weighted average sale price: $37.5431 per share
Shares sold by Managed Account: 13315 shares
+3 more
6 metrics
Total shares sold
28315 shares
Aggregate Eton Pharmaceuticals common stock sold on 2026-07-14 by affiliated accounts
Weighted average sale price
$37.5431 per share
Average price for the July 14, 2026 common stock sales
Shares sold by Managed Account
13315 shares
Common stock sold indirectly via a separately managed account on 2026-07-14
Shares sold by Opaleye, L.P.
15000 shares
Common stock sold indirectly via Opaleye, L.P. on 2026-07-14
Shares held by Managed Account after sale
40000 shares
Indirect common stock holdings in Eton Pharmaceuticals after the reported sale
Shares held by Opaleye, L.P. after sale
2665000 shares
Indirect common stock holdings in Eton Pharmaceuticals after the reported sale
Key Terms
Section 16, weighted average price, separately managed account, beneficially own, +1 more
5 terms
Section 16 regulatory
"no longer subject to Section 16."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
separately managed account financial
"Securities owned by a separately managed account (the "Managed Account")."
A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.
beneficially own regulatory
"may be deemed to beneficially own the securities owned directly by the Fund."
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest regulatory
"disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider sales did Opaleye Management report for Eton Pharmaceuticals (ETON)?
Opaleye Management reported selling 28,315 shares of Eton Pharmaceuticals common stock on July 14, 2026. The sales comprised 13,315 shares from a separately managed account and 15,000 shares from Opaleye, L.P., both reported as indirect holdings.
Was Opaleye Management’s ETON trade made under a Rule 10b5-1 trading plan?
No. The Rule 10b5-1 checkbox is not checked, and there is no footnote indicating a trading plan. That means these reported sales are not affirmatively identified as having been executed under a pre-arranged Rule 10b5-1 plan.
Why was Eton Pharmaceuticals’ (ETON) Form 4/A filed as an amendment?
The amendment was filed solely to check the box indicating Opaleye Management is no longer subject to Section 16. The underlying transaction details remain the same; the change is to update the reporting-status checkbox.